I have been reading a great deal this last month about progestins/progesterone/prometrium. The first thing we need to realize is that while all of these drugs have an effect on the progesterone receptor they are not equal.
All first, second, third and most fourth generational progestins are derived from testosterone. As a result all but the atypical fourth generational progestin drospirenone have an affinity for testosterone receptors. This causes the unwanted side effects. Some are worse than others, particularly norgesterel. The most common form of progestin is medroxy progesterone. It has less affinity for testosterone receptors but can act on them.
Drospirenone is derived from spironolactone and as such it has no ability to activate testosterone receptors giving it a very good side effect profile. In the US it is marketed as AngeliQ in combination with 17b estradiol. It is approved for HRT and is not a contraceptive.
Prometrium or micronized progesterone is derived from plant sources and is considered much better than the synthetic versions. However some people still have unwanted side effects on it and the exact physiologic reason for it is not clear. Maybe these side effects are caused by rapidly titrating the dose and a slower approach could be helpful.
The important fact is that these drugs are all different however they are in many studies just described as progesterone and one needs to read the whole report to find that they were using medroxyprogesterone and making generalized statements about progesterone.
One last progestin that we here in the US have little experience with is cyproterone acetate. It is described as an antiandrogen in most transgender literature and even though that is true it also has an effect on progesterone receptors.
I don't want to say one is better than another because we are all individules and are a study of one. Some may not work for you on the first try. Maybe they can be tried again later and work better. We are not stable in any way nor are we alike biochemically and we need to be flexible in our approach. Working with rigid drs doesn't lead to effective transformation
http://www.ncbi.nlm.nih.gov/m/pubmed/8922878/Huggs
Emily